Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 326 | 2025 | 21056 | 15.630 |
Why?
|
Antineoplastic Agents, Hormonal | 41 | 2024 | 1534 | 6.230 |
Why?
|
Mastectomy | 33 | 2024 | 1847 | 4.520 |
Why?
|
Pregnancy Complications, Neoplastic | 17 | 2024 | 258 | 4.500 |
Why?
|
Chemotherapy, Adjuvant | 71 | 2024 | 3537 | 3.810 |
Why?
|
Ovary | 20 | 2022 | 956 | 3.710 |
Why?
|
Premenopause | 25 | 2022 | 1037 | 3.280 |
Why?
|
Fertility | 21 | 2024 | 768 | 3.140 |
Why?
|
Survivors | 42 | 2024 | 2372 | 2.920 |
Why?
|
Receptor, erbB-2 | 40 | 2024 | 2593 | 2.750 |
Why?
|
Tamoxifen | 21 | 2024 | 963 | 2.700 |
Why?
|
Quality of Life | 55 | 2025 | 13462 | 2.570 |
Why?
|
Decision Making | 25 | 2023 | 3965 | 2.530 |
Why?
|
Amenorrhea | 15 | 2021 | 470 | 2.440 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 14 | 2024 | 920 | 2.380 |
Why?
|
Infertility, Female | 12 | 2019 | 763 | 2.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 47 | 2024 | 11868 | 2.090 |
Why?
|
Antineoplastic Agents | 41 | 2022 | 13648 | 2.020 |
Why?
|
Female | 367 | 2025 | 396112 | 1.940 |
Why?
|
Anxiety | 23 | 2022 | 4671 | 1.930 |
Why?
|
Neoplasms | 43 | 2024 | 22340 | 1.870 |
Why?
|
Carcinoma, Ductal, Breast | 12 | 2023 | 1083 | 1.860 |
Why?
|
Receptors, Estrogen | 26 | 2024 | 2242 | 1.780 |
Why?
|
Adult | 220 | 2025 | 223044 | 1.690 |
Why?
|
Neoplasm Recurrence, Local | 34 | 2024 | 9373 | 1.680 |
Why?
|
Primary Ovarian Insufficiency | 9 | 2021 | 104 | 1.650 |
Why?
|
Medication Adherence | 14 | 2024 | 2192 | 1.650 |
Why?
|
Mastectomy, Segmental | 16 | 2024 | 964 | 1.620 |
Why?
|
Aromatase Inhibitors | 10 | 2024 | 518 | 1.560 |
Why?
|
Carcinoma in Situ | 4 | 2022 | 779 | 1.500 |
Why?
|
Neoadjuvant Therapy | 16 | 2024 | 2895 | 1.460 |
Why?
|
Humans | 404 | 2025 | 765968 | 1.450 |
Why?
|
Gonadotropin-Releasing Hormone | 11 | 2018 | 1133 | 1.320 |
Why?
|
Sexual Partners | 4 | 2023 | 804 | 1.310 |
Why?
|
BRCA2 Protein | 8 | 2024 | 800 | 1.280 |
Why?
|
Sexual Dysfunction, Physiological | 4 | 2023 | 363 | 1.250 |
Why?
|
Receptors, Progesterone | 14 | 2024 | 1153 | 1.240 |
Why?
|
Young Adult | 71 | 2025 | 59889 | 1.170 |
Why?
|
Clinical Trials as Topic | 23 | 2024 | 8041 | 1.140 |
Why?
|
Prospective Studies | 58 | 2024 | 54802 | 1.140 |
Why?
|
Neoplasms, Second Primary | 3 | 2024 | 1050 | 1.120 |
Why?
|
Neoplasm Staging | 36 | 2024 | 11206 | 1.110 |
Why?
|
Breast Neoplasms, Male | 6 | 2019 | 212 | 1.100 |
Why?
|
Paclitaxel | 17 | 2024 | 1728 | 1.090 |
Why?
|
Pregnancy | 51 | 2024 | 30260 | 1.080 |
Why?
|
Patient Compliance | 8 | 2014 | 2692 | 1.060 |
Why?
|
BRCA1 Protein | 9 | 2024 | 1153 | 1.060 |
Why?
|
Infertility | 7 | 2021 | 654 | 1.040 |
Why?
|
Age Factors | 39 | 2024 | 18380 | 0.980 |
Why?
|
Health Knowledge, Attitudes, Practice | 10 | 2024 | 4058 | 0.950 |
Why?
|
Medical Oncology | 19 | 2023 | 2339 | 0.930 |
Why?
|
Adaptation, Psychological | 8 | 2023 | 2660 | 0.900 |
Why?
|
Depression | 20 | 2024 | 8237 | 0.890 |
Why?
|
Breast Feeding | 2 | 2024 | 1364 | 0.870 |
Why?
|
Fatigue | 13 | 2024 | 1549 | 0.870 |
Why?
|
Menopause | 8 | 2024 | 1659 | 0.860 |
Why?
|
Middle Aged | 141 | 2024 | 223009 | 0.830 |
Why?
|
Body Image | 5 | 2020 | 644 | 0.820 |
Why?
|
Nitriles | 6 | 2024 | 982 | 0.800 |
Why?
|
Ovariectomy | 5 | 2024 | 611 | 0.800 |
Why?
|
Attitude to Health | 4 | 2019 | 2020 | 0.790 |
Why?
|
Perception | 6 | 2024 | 1205 | 0.780 |
Why?
|
Hormones | 4 | 2022 | 863 | 0.770 |
Why?
|
Triazoles | 5 | 2024 | 897 | 0.770 |
Why?
|
Genes, BRCA2 | 8 | 2024 | 588 | 0.760 |
Why?
|
Patient Participation | 8 | 2019 | 1455 | 0.760 |
Why?
|
Disease-Free Survival | 22 | 2024 | 6832 | 0.760 |
Why?
|
Patient Preference | 3 | 2018 | 952 | 0.740 |
Why?
|
Sleep Initiation and Maintenance Disorders | 6 | 2023 | 1090 | 0.710 |
Why?
|
Genetic Testing | 8 | 2022 | 3595 | 0.710 |
Why?
|
Genes, BRCA1 | 7 | 2024 | 750 | 0.700 |
Why?
|
Oxazoles | 1 | 2021 | 198 | 0.690 |
Why?
|
Cryopreservation | 8 | 2024 | 728 | 0.660 |
Why?
|
Pyridines | 5 | 2024 | 2888 | 0.660 |
Why?
|
Sexual Behavior | 5 | 2023 | 2193 | 0.650 |
Why?
|
Disclosure | 4 | 2009 | 756 | 0.640 |
Why?
|
Social Support | 8 | 2024 | 2192 | 0.640 |
Why?
|
Mammography | 6 | 2023 | 2423 | 0.640 |
Why?
|
Clinical Trials, Phase III as Topic | 6 | 2021 | 878 | 0.630 |
Why?
|
Research Subjects | 2 | 2015 | 247 | 0.620 |
Why?
|
Patient Education as Topic | 16 | 2024 | 2334 | 0.620 |
Why?
|
Pregnancy Rate | 4 | 2020 | 655 | 0.600 |
Why?
|
Prognosis | 28 | 2024 | 29922 | 0.600 |
Why?
|
Socioeconomic Factors | 12 | 2021 | 7838 | 0.590 |
Why?
|
Patient Satisfaction | 12 | 2021 | 3475 | 0.590 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 532 | 0.570 |
Why?
|
Communication | 10 | 2022 | 3916 | 0.570 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2019 | 193 | 0.560 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2025 | 10383 | 0.560 |
Why?
|
Hot Flashes | 8 | 2024 | 330 | 0.550 |
Why?
|
Reproductive History | 2 | 2015 | 210 | 0.540 |
Why?
|
Aged | 91 | 2024 | 171117 | 0.540 |
Why?
|
Breast | 9 | 2023 | 1946 | 0.540 |
Why?
|
Withholding Treatment | 3 | 2023 | 621 | 0.530 |
Why?
|
Transplantation Conditioning | 1 | 2023 | 1635 | 0.530 |
Why?
|
Molecular Targeted Therapy | 5 | 2020 | 2822 | 0.530 |
Why?
|
Goserelin | 3 | 2019 | 126 | 0.530 |
Why?
|
Patient Selection | 7 | 2020 | 4255 | 0.520 |
Why?
|
Expert Testimony | 2 | 2017 | 266 | 0.520 |
Why?
|
Patient Care Planning | 5 | 2019 | 906 | 0.520 |
Why?
|
Fluorouracil | 7 | 2019 | 1648 | 0.520 |
Why?
|
Parity | 4 | 2015 | 931 | 0.520 |
Why?
|
Antimetabolites, Antineoplastic | 4 | 2019 | 647 | 0.510 |
Why?
|
Exercise Therapy | 3 | 2019 | 937 | 0.510 |
Why?
|
Oocyte Retrieval | 1 | 2017 | 163 | 0.500 |
Why?
|
Parenting | 1 | 2022 | 709 | 0.500 |
Why?
|
Carcinoma | 3 | 2021 | 2312 | 0.500 |
Why?
|
Estrogen Receptor Modulators | 1 | 2015 | 58 | 0.490 |
Why?
|
Combined Modality Therapy | 13 | 2023 | 8529 | 0.490 |
Why?
|
Outpatients | 1 | 2023 | 1595 | 0.490 |
Why?
|
Quinazolines | 2 | 2021 | 1364 | 0.490 |
Why?
|
Adolescent | 33 | 2025 | 88835 | 0.480 |
Why?
|
United States | 43 | 2024 | 72903 | 0.470 |
Why?
|
Continuity of Patient Care | 6 | 2021 | 1078 | 0.470 |
Why?
|
Telemedicine | 5 | 2025 | 3105 | 0.470 |
Why?
|
Risk Factors | 35 | 2024 | 74840 | 0.470 |
Why?
|
Practice Guidelines as Topic | 14 | 2024 | 7425 | 0.470 |
Why?
|
Pregnancy Outcome | 7 | 2024 | 2966 | 0.470 |
Why?
|
Employment | 3 | 2022 | 1106 | 0.460 |
Why?
|
Personal Autonomy | 1 | 2017 | 315 | 0.460 |
Why?
|
Cohort Studies | 27 | 2024 | 41649 | 0.460 |
Why?
|
Hematopoiesis | 2 | 2023 | 2058 | 0.450 |
Why?
|
Deoxycytidine | 5 | 2012 | 889 | 0.450 |
Why?
|
Antineoplastic Protocols | 1 | 2014 | 47 | 0.450 |
Why?
|
Attitude of Health Personnel | 5 | 2018 | 3925 | 0.450 |
Why?
|
Oocytes | 3 | 2017 | 1169 | 0.450 |
Why?
|
Physicians | 6 | 2019 | 4588 | 0.450 |
Why?
|
Cyclophosphamide | 11 | 2021 | 2228 | 0.450 |
Why?
|
Menopause, Premature | 5 | 2021 | 124 | 0.440 |
Why?
|
Communication Barriers | 1 | 2017 | 418 | 0.440 |
Why?
|
Stress, Psychological | 6 | 2023 | 4533 | 0.440 |
Why?
|
Physician-Patient Relations | 11 | 2019 | 3278 | 0.440 |
Why?
|
Gonadal Steroid Hormones | 1 | 2018 | 705 | 0.440 |
Why?
|
Standard of Care | 2 | 2015 | 567 | 0.430 |
Why?
|
Hormone Replacement Therapy | 2 | 2024 | 753 | 0.430 |
Why?
|
Thrombotic Microangiopathies | 2 | 2012 | 125 | 0.430 |
Why?
|
Qualitative Research | 3 | 2023 | 3139 | 0.430 |
Why?
|
Risk Assessment | 20 | 2021 | 24282 | 0.420 |
Why?
|
Carcinoma, Lobular | 1 | 2017 | 471 | 0.420 |
Why?
|
Treatment Outcome | 40 | 2024 | 65188 | 0.420 |
Why?
|
Research Design | 7 | 2022 | 6209 | 0.410 |
Why?
|
Spouses | 1 | 2015 | 288 | 0.400 |
Why?
|
Women | 1 | 2014 | 226 | 0.400 |
Why?
|
Patient Advocacy | 2 | 2012 | 361 | 0.390 |
Why?
|
Brain Neoplasms | 3 | 2024 | 9071 | 0.390 |
Why?
|
Health Education | 1 | 2019 | 1060 | 0.390 |
Why?
|
Income | 2 | 2020 | 1874 | 0.390 |
Why?
|
Inpatients | 1 | 2023 | 2564 | 0.380 |
Why?
|
Delayed Diagnosis | 2 | 2013 | 452 | 0.380 |
Why?
|
Survival Rate | 12 | 2024 | 12795 | 0.380 |
Why?
|
Obesity | 6 | 2023 | 13076 | 0.380 |
Why?
|
Caregivers | 1 | 2023 | 2307 | 0.360 |
Why?
|
Models, Organizational | 1 | 2014 | 547 | 0.360 |
Why?
|
Ovulation Induction | 3 | 2024 | 277 | 0.360 |
Why?
|
Administration, Oral | 9 | 2024 | 4015 | 0.360 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2013 | 409 | 0.350 |
Why?
|
Neoplasm, Residual | 5 | 2024 | 1009 | 0.350 |
Why?
|
Follow-Up Studies | 24 | 2024 | 39193 | 0.350 |
Why?
|
Live Birth | 3 | 2023 | 516 | 0.340 |
Why?
|
Rare Diseases | 1 | 2015 | 635 | 0.330 |
Why?
|
Embryo, Mammalian | 2 | 2015 | 1673 | 0.330 |
Why?
|
Mediastinal Diseases | 2 | 2000 | 91 | 0.330 |
Why?
|
Meditation | 2 | 2024 | 256 | 0.330 |
Why?
|
Drug Administration Schedule | 6 | 2015 | 4850 | 0.320 |
Why?
|
Biomedical Research | 5 | 2019 | 3458 | 0.320 |
Why?
|
Follicle Stimulating Hormone | 2 | 2009 | 731 | 0.320 |
Why?
|
Piperazines | 3 | 2024 | 2549 | 0.320 |
Why?
|
Aged, 80 and over | 32 | 2024 | 59489 | 0.310 |
Why?
|
Lymphatic Diseases | 2 | 2000 | 317 | 0.300 |
Why?
|
Tumor Burden | 5 | 2017 | 1885 | 0.300 |
Why?
|
Time Factors | 16 | 2024 | 40065 | 0.300 |
Why?
|
Body Mass Index | 8 | 2023 | 13039 | 0.290 |
Why?
|
Genetic Predisposition to Disease | 9 | 2023 | 18071 | 0.290 |
Why?
|
Exercise | 9 | 2023 | 5937 | 0.290 |
Why?
|
Germ-Line Mutation | 6 | 2024 | 1884 | 0.290 |
Why?
|
Logistic Models | 10 | 2018 | 13266 | 0.290 |
Why?
|
Educational Status | 5 | 2019 | 2513 | 0.290 |
Why?
|
Ovarian Follicle | 1 | 2009 | 243 | 0.280 |
Why?
|
Interpersonal Relations | 1 | 2015 | 1432 | 0.280 |
Why?
|
Phytoestrogens | 1 | 2007 | 59 | 0.280 |
Why?
|
Lymph Node Excision | 4 | 2024 | 1259 | 0.280 |
Why?
|
Overweight | 3 | 2022 | 2444 | 0.280 |
Why?
|
Radiotherapy, Adjuvant | 6 | 2024 | 1776 | 0.280 |
Why?
|
Germ Cells | 5 | 2023 | 647 | 0.280 |
Why?
|
Odds Ratio | 7 | 2020 | 9649 | 0.280 |
Why?
|
Proportional Hazards Models | 11 | 2024 | 12509 | 0.270 |
Why?
|
Dyspnea | 2 | 2012 | 1352 | 0.270 |
Why?
|
Longitudinal Studies | 12 | 2022 | 14751 | 0.270 |
Why?
|
Survival Analysis | 12 | 2024 | 10070 | 0.270 |
Why?
|
Feasibility Studies | 6 | 2019 | 5302 | 0.270 |
Why?
|
Health Behavior | 3 | 2022 | 2650 | 0.270 |
Why?
|
Estrogen Receptor alpha | 2 | 2021 | 578 | 0.270 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3251 | 0.260 |
Why?
|
Program Development | 1 | 2012 | 1295 | 0.260 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2014 | 953 | 0.260 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2024 | 4628 | 0.260 |
Why?
|
Neoplasm Metastasis | 11 | 2021 | 4893 | 0.250 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 5753 | 0.250 |
Why?
|
Women's Health | 2 | 2015 | 2084 | 0.250 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2024 | 561 | 0.250 |
Why?
|
Placebos | 3 | 2021 | 1659 | 0.240 |
Why?
|
Neoplastic Cells, Circulating | 3 | 2021 | 950 | 0.240 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2056 | 0.240 |
Why?
|
Palliative Care | 2 | 2024 | 3645 | 0.240 |
Why?
|
Patients | 3 | 2011 | 910 | 0.240 |
Why?
|
Genomics | 4 | 2024 | 5929 | 0.230 |
Why?
|
Ovarian Neoplasms | 3 | 2018 | 4900 | 0.230 |
Why?
|
Physical Fitness | 4 | 2017 | 742 | 0.230 |
Why?
|
Disease Management | 7 | 2018 | 2535 | 0.230 |
Why?
|
Consensus | 6 | 2024 | 3202 | 0.230 |
Why?
|
Lymphatic Metastasis | 5 | 2021 | 2887 | 0.230 |
Why?
|
Mental Health | 1 | 2019 | 3278 | 0.230 |
Why?
|
Cross-Sectional Studies | 12 | 2022 | 26318 | 0.220 |
Why?
|
Cisplatin | 3 | 2020 | 1658 | 0.220 |
Why?
|
Anthracyclines | 3 | 2021 | 284 | 0.220 |
Why?
|
Reproductive Techniques, Assisted | 3 | 2024 | 501 | 0.220 |
Why?
|
Directive Counseling | 2 | 2015 | 171 | 0.220 |
Why?
|
Life Style | 6 | 2023 | 3926 | 0.220 |
Why?
|
Heart | 2 | 2016 | 4414 | 0.220 |
Why?
|
Confidence Intervals | 4 | 2020 | 2910 | 0.220 |
Why?
|
Mutation | 12 | 2023 | 30198 | 0.220 |
Why?
|
Family | 3 | 2023 | 3209 | 0.220 |
Why?
|
Data Collection | 6 | 2013 | 3318 | 0.210 |
Why?
|
Incidence | 8 | 2024 | 21480 | 0.210 |
Why?
|
Age of Onset | 4 | 2016 | 3344 | 0.210 |
Why?
|
Early Detection of Cancer | 6 | 2019 | 3236 | 0.210 |
Why?
|
North America | 2 | 2024 | 1285 | 0.200 |
Why?
|
Cost of Illness | 3 | 2024 | 1950 | 0.200 |
Why?
|
Research Support as Topic | 1 | 2007 | 696 | 0.200 |
Why?
|
Registries | 5 | 2019 | 8297 | 0.200 |
Why?
|
Lymph Nodes | 4 | 2023 | 3454 | 0.200 |
Why?
|
Age Distribution | 2 | 2020 | 2858 | 0.200 |
Why?
|
Adjuvants, Immunologic | 3 | 2022 | 995 | 0.200 |
Why?
|
Body Weight | 4 | 2022 | 4622 | 0.200 |
Why?
|
Heterozygote | 3 | 2024 | 2794 | 0.200 |
Why?
|
Androstadienes | 1 | 2024 | 347 | 0.200 |
Why?
|
Anti-Mullerian Hormone | 3 | 2021 | 420 | 0.200 |
Why?
|
Retrospective Studies | 25 | 2024 | 81514 | 0.190 |
Why?
|
Treatment Refusal | 2 | 2018 | 433 | 0.190 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2023 | 116 | 0.190 |
Why?
|
Ethics, Clinical | 1 | 2002 | 101 | 0.190 |
Why?
|
Mass Screening | 5 | 2014 | 5446 | 0.190 |
Why?
|
Male | 50 | 2024 | 363698 | 0.190 |
Why?
|
Fear | 3 | 2021 | 1499 | 0.190 |
Why?
|
Cancer Care Facilities | 3 | 2016 | 426 | 0.180 |
Why?
|
Pilot Projects | 10 | 2019 | 8733 | 0.180 |
Why?
|
Cytochrome P-450 CYP2D6 | 2 | 2013 | 108 | 0.180 |
Why?
|
Contraceptive Agents | 1 | 2022 | 147 | 0.180 |
Why?
|
Resource Allocation | 2 | 2013 | 354 | 0.180 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2024 | 352 | 0.180 |
Why?
|
Population Surveillance | 4 | 2019 | 2590 | 0.180 |
Why?
|
Hypertension, Pulmonary | 1 | 2011 | 1604 | 0.180 |
Why?
|
Evidence-Based Medicine | 7 | 2021 | 3685 | 0.180 |
Why?
|
Mammaplasty | 4 | 2021 | 1264 | 0.180 |
Why?
|
Maytansine | 1 | 2021 | 87 | 0.180 |
Why?
|
Camptothecin | 1 | 2024 | 600 | 0.180 |
Why?
|
Temperance | 1 | 2020 | 88 | 0.180 |
Why?
|
Multivariate Analysis | 4 | 2019 | 12056 | 0.170 |
Why?
|
Taxoids | 2 | 2022 | 665 | 0.170 |
Why?
|
Drug Industry | 1 | 2007 | 791 | 0.170 |
Why?
|
Sentinel Lymph Node Biopsy | 4 | 2023 | 728 | 0.170 |
Why?
|
Patient-Centered Care | 3 | 2023 | 1458 | 0.170 |
Why?
|
Peripheral Nervous System Diseases | 3 | 2019 | 712 | 0.170 |
Why?
|
Self Report | 4 | 2016 | 3770 | 0.170 |
Why?
|
Multicenter Studies as Topic | 2 | 2021 | 1731 | 0.170 |
Why?
|
Publishing | 1 | 2007 | 835 | 0.170 |
Why?
|
Ketones | 1 | 2020 | 183 | 0.160 |
Why?
|
Furans | 1 | 2020 | 198 | 0.160 |
Why?
|
SEER Program | 2 | 2021 | 1446 | 0.160 |
Why?
|
Switzerland | 4 | 2022 | 322 | 0.160 |
Why?
|
Child | 15 | 2024 | 80564 | 0.160 |
Why?
|
Doxorubicin | 6 | 2019 | 2230 | 0.160 |
Why?
|
Methotrexate | 5 | 2019 | 1722 | 0.160 |
Why?
|
Truth Disclosure | 1 | 2003 | 433 | 0.160 |
Why?
|
Weight Loss | 5 | 2022 | 2710 | 0.160 |
Why?
|
Recurrence | 5 | 2019 | 8501 | 0.150 |
Why?
|
Internet | 5 | 2021 | 3106 | 0.150 |
Why?
|
Vaginal Diseases | 1 | 2019 | 103 | 0.150 |
Why?
|
Leukemia | 2 | 2023 | 1522 | 0.150 |
Why?
|
Lung Neoplasms | 4 | 2019 | 13451 | 0.150 |
Why?
|
Genetic Counseling | 2 | 2014 | 634 | 0.150 |
Why?
|
Female Urogenital Diseases | 1 | 2018 | 57 | 0.150 |
Why?
|
Double-Blind Method | 4 | 2024 | 12437 | 0.140 |
Why?
|
Societies, Medical | 5 | 2018 | 3956 | 0.140 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 3715 | 0.140 |
Why?
|
Decision Support Techniques | 4 | 2020 | 2003 | 0.140 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2019 | 150 | 0.140 |
Why?
|
Prevalence | 5 | 2024 | 15842 | 0.140 |
Why?
|
Unemployment | 1 | 2019 | 211 | 0.140 |
Why?
|
Axilla | 4 | 2023 | 615 | 0.140 |
Why?
|
Leuprolide | 1 | 2019 | 312 | 0.140 |
Why?
|
Epothilones | 2 | 2021 | 43 | 0.140 |
Why?
|
Counseling | 3 | 2020 | 1551 | 0.140 |
Why?
|
Acute Kidney Injury | 2 | 2020 | 1946 | 0.140 |
Why?
|
Lactation | 1 | 2019 | 391 | 0.140 |
Why?
|
Menstrual Cycle | 2 | 2011 | 540 | 0.140 |
Why?
|
Nutrition Surveys | 1 | 2024 | 1741 | 0.130 |
Why?
|
Risk | 7 | 2024 | 9591 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2024 | 981 | 0.130 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 999 | 0.130 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2000 | 616 | 0.130 |
Why?
|
Lung | 2 | 2012 | 10033 | 0.130 |
Why?
|
ras GTPase-Activating Proteins | 1 | 2016 | 95 | 0.130 |
Why?
|
Antibodies, Monoclonal | 3 | 2010 | 9249 | 0.130 |
Why?
|
Infant, Newborn | 4 | 2023 | 26346 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2019 | 679 | 0.130 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2024 | 1736 | 0.120 |
Why?
|
Social Class | 2 | 2018 | 2007 | 0.120 |
Why?
|
Acupuncture Therapy | 1 | 2019 | 466 | 0.120 |
Why?
|
Pathology, Clinical | 1 | 2019 | 377 | 0.120 |
Why?
|
Massachusetts | 4 | 2014 | 8875 | 0.120 |
Why?
|
Libido | 1 | 2015 | 123 | 0.120 |
Why?
|
Community Health Centers | 1 | 2019 | 469 | 0.120 |
Why?
|
Psychotherapy, Brief | 1 | 2016 | 118 | 0.120 |
Why?
|
Sweating | 1 | 2015 | 155 | 0.120 |
Why?
|
Transplantation, Homologous | 1 | 2023 | 4860 | 0.120 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 2268 | 0.110 |
Why?
|
Nurses | 1 | 2004 | 2505 | 0.110 |
Why?
|
Patient Care Team | 3 | 2014 | 2517 | 0.110 |
Why?
|
Neoplasm Invasiveness | 4 | 2017 | 3602 | 0.110 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1378 | 0.110 |
Why?
|
Estradiol | 2 | 2013 | 1947 | 0.110 |
Why?
|
Lupus Erythematosus, Systemic | 5 | 2003 | 2159 | 0.110 |
Why?
|
Videoconferencing | 1 | 2016 | 209 | 0.110 |
Why?
|
Gene Expression Profiling | 3 | 2024 | 9525 | 0.110 |
Why?
|
Colorado | 1 | 2014 | 167 | 0.110 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2015 | 6014 | 0.110 |
Why?
|
Models, Psychological | 1 | 2018 | 824 | 0.110 |
Why?
|
Health Status Disparities | 2 | 2015 | 1880 | 0.110 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2022 | 633 | 0.110 |
Why?
|
Cause of Death | 3 | 2024 | 3708 | 0.110 |
Why?
|
Spirituality | 1 | 2018 | 430 | 0.100 |
Why?
|
Embryo Transfer | 1 | 2017 | 525 | 0.100 |
Why?
|
Echocardiography | 3 | 2016 | 5045 | 0.100 |
Why?
|
Hepatitis C | 1 | 2023 | 1597 | 0.100 |
Why?
|
Amyloidosis | 1 | 2000 | 885 | 0.100 |
Why?
|
Menarche | 2 | 2013 | 532 | 0.100 |
Why?
|
Aspirin | 1 | 2024 | 3134 | 0.100 |
Why?
|
Sarcoma | 1 | 2023 | 1802 | 0.100 |
Why?
|
Hodgkin Disease | 1 | 2020 | 1383 | 0.100 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2023 | 2942 | 0.100 |
Why?
|
Europe | 4 | 2022 | 3423 | 0.100 |
Why?
|
Primary Health Care | 2 | 2022 | 4736 | 0.100 |
Why?
|
American Cancer Society | 1 | 2012 | 69 | 0.100 |
Why?
|
Psychotherapy, Group | 1 | 2016 | 416 | 0.100 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2015 | 287 | 0.100 |
Why?
|
Canada | 2 | 2024 | 2119 | 0.100 |
Why?
|
Heart Ventricles | 2 | 2016 | 3832 | 0.100 |
Why?
|
Estrogen Replacement Therapy | 1 | 2018 | 1206 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2024 | 5125 | 0.090 |
Why?
|
Radiation Oncology | 1 | 2018 | 569 | 0.090 |
Why?
|
Prejudice | 1 | 2015 | 567 | 0.090 |
Why?
|
Self Care | 2 | 2013 | 800 | 0.090 |
Why?
|
Environment Design | 1 | 2013 | 174 | 0.090 |
Why?
|
Healthcare Disparities | 3 | 2015 | 3413 | 0.090 |
Why?
|
Models, Theoretical | 1 | 2003 | 3564 | 0.090 |
Why?
|
Developing Countries | 2 | 2013 | 2911 | 0.090 |
Why?
|
Sleep Disorders, Intrinsic | 1 | 2010 | 16 | 0.090 |
Why?
|
Appointments and Schedules | 1 | 2014 | 444 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 2033 | 0.090 |
Why?
|
Inservice Training | 1 | 2013 | 375 | 0.090 |
Why?
|
Mandatory Testing | 1 | 2010 | 23 | 0.090 |
Why?
|
Benzothiazoles | 1 | 2011 | 246 | 0.090 |
Why?
|
Micro-Electrical-Mechanical Systems | 1 | 2010 | 29 | 0.090 |
Why?
|
Fatal Outcome | 2 | 2012 | 1831 | 0.090 |
Why?
|
Pain | 2 | 2022 | 5077 | 0.080 |
Why?
|
Cyclohexanols | 1 | 2010 | 127 | 0.080 |
Why?
|
Anthropometry | 2 | 2012 | 1338 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2017 | 2424 | 0.080 |
Why?
|
Premature Birth | 1 | 2022 | 1829 | 0.080 |
Why?
|
Research Report | 1 | 2012 | 367 | 0.080 |
Why?
|
Diet | 1 | 2007 | 8086 | 0.080 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15398 | 0.080 |
Why?
|
Long-Term Care | 1 | 2013 | 629 | 0.080 |
Why?
|
Weight Gain | 4 | 2022 | 2355 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 2045 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2013 | 10729 | 0.080 |
Why?
|
Italy | 2 | 2022 | 854 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1761 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2020 | 2084 | 0.080 |
Why?
|
Medical Records | 2 | 2009 | 1409 | 0.080 |
Why?
|
Informed Consent | 1 | 2015 | 1010 | 0.080 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2009 | 134 | 0.080 |
Why?
|
Inhibins | 1 | 2009 | 211 | 0.080 |
Why?
|
Disabled Persons | 2 | 1997 | 1208 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2780 | 0.080 |
Why?
|
Risk Reduction Behavior | 1 | 2015 | 1123 | 0.070 |
Why?
|
Embryo Culture Techniques | 1 | 2009 | 84 | 0.070 |
Why?
|
Disease Progression | 3 | 2024 | 13632 | 0.070 |
Why?
|
Vaginitis | 1 | 2008 | 50 | 0.070 |
Why?
|
NF-kappa B | 1 | 2016 | 2485 | 0.070 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2000 | 2531 | 0.070 |
Why?
|
Penetrance | 2 | 2022 | 388 | 0.070 |
Why?
|
Personal Satisfaction | 1 | 2012 | 641 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2021 | 3800 | 0.070 |
Why?
|
Genistein | 1 | 2007 | 87 | 0.070 |
Why?
|
Diagnosis, Differential | 4 | 2012 | 12976 | 0.070 |
Why?
|
Inflammation | 2 | 2024 | 10850 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6499 | 0.070 |
Why?
|
Advance Directives | 1 | 2009 | 251 | 0.070 |
Why?
|
Reproduction | 1 | 2012 | 641 | 0.070 |
Why?
|
Melanoma | 2 | 2023 | 5719 | 0.070 |
Why?
|
Medicaid | 3 | 2012 | 2833 | 0.070 |
Why?
|
Drug Monitoring | 2 | 2010 | 962 | 0.070 |
Why?
|
Heart Rate | 1 | 2018 | 4204 | 0.070 |
Why?
|
Congresses as Topic | 1 | 2012 | 811 | 0.070 |
Why?
|
Lignans | 1 | 2007 | 82 | 0.070 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2015 | 639 | 0.070 |
Why?
|
Genotype | 4 | 2019 | 13024 | 0.070 |
Why?
|
Referral and Consultation | 2 | 2017 | 3615 | 0.070 |
Why?
|
Isoflavones | 1 | 2007 | 139 | 0.070 |
Why?
|
Postmenopause | 2 | 2024 | 2515 | 0.070 |
Why?
|
Emotions | 2 | 2015 | 2763 | 0.070 |
Why?
|
Myelodysplastic Syndromes | 1 | 2016 | 1404 | 0.070 |
Why?
|
Radiotherapy | 3 | 2017 | 1494 | 0.070 |
Why?
|
Arousal | 1 | 2012 | 1171 | 0.070 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5370 | 0.060 |
Why?
|
Health Surveys | 2 | 2013 | 4056 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2007 | 641 | 0.060 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15880 | 0.060 |
Why?
|
Research | 1 | 2014 | 1975 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 16047 | 0.060 |
Why?
|
Fertility Agents | 1 | 2005 | 11 | 0.060 |
Why?
|
Advisory Committees | 1 | 2009 | 796 | 0.060 |
Why?
|
Physical Endurance | 1 | 2008 | 368 | 0.060 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2006 | 239 | 0.060 |
Why?
|
Case-Control Studies | 4 | 2021 | 22223 | 0.060 |
Why?
|
Drug Utilization | 2 | 2002 | 1187 | 0.060 |
Why?
|
Mexico | 2 | 2018 | 777 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2844 | 0.060 |
Why?
|
Thinking | 2 | 2021 | 322 | 0.060 |
Why?
|
Professional Practice | 1 | 2007 | 313 | 0.060 |
Why?
|
Reproductive Medicine | 1 | 2006 | 97 | 0.060 |
Why?
|
Internationality | 2 | 2024 | 1007 | 0.060 |
Why?
|
Terminology as Topic | 1 | 2012 | 1534 | 0.060 |
Why?
|
Osteoporosis | 1 | 2014 | 1582 | 0.060 |
Why?
|
Insurance Coverage | 1 | 2015 | 1944 | 0.060 |
Why?
|
Insurance, Health | 2 | 2015 | 2521 | 0.060 |
Why?
|
Syndrome | 2 | 2022 | 3271 | 0.060 |
Why?
|
Salpingectomy | 1 | 2024 | 45 | 0.060 |
Why?
|
Neoplastic Processes | 1 | 2023 | 35 | 0.060 |
Why?
|
Medication Errors | 1 | 2010 | 786 | 0.060 |
Why?
|
Authorship | 1 | 2007 | 288 | 0.050 |
Why?
|
Nurse-Patient Relations | 1 | 2004 | 102 | 0.050 |
Why?
|
Neutropenia | 2 | 2006 | 893 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2016 | 4913 | 0.050 |
Why?
|
Regression Analysis | 2 | 2015 | 6322 | 0.050 |
Why?
|
Muscle Strength | 1 | 2008 | 637 | 0.050 |
Why?
|
Preoperative Care | 1 | 2012 | 2267 | 0.050 |
Why?
|
Biopsy | 2 | 2017 | 6763 | 0.050 |
Why?
|
Ventricular Function, Left | 1 | 2016 | 3928 | 0.050 |
Why?
|
Smoking | 3 | 2020 | 9081 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 2 | 2014 | 3230 | 0.050 |
Why?
|
Pulmonary Artery | 1 | 2011 | 1935 | 0.050 |
Why?
|
Genome-Wide Association Study | 2 | 2019 | 12807 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2019 | 8611 | 0.050 |
Why?
|
Telephone | 2 | 2020 | 627 | 0.050 |
Why?
|
Phenotype | 1 | 2020 | 16721 | 0.050 |
Why?
|
New Jersey | 1 | 2003 | 296 | 0.050 |
Why?
|
Hypnotics and Sedatives | 1 | 2010 | 1191 | 0.050 |
Why?
|
Quality Assurance, Health Care | 1 | 2012 | 2172 | 0.050 |
Why?
|
Chi-Square Distribution | 2 | 2021 | 3432 | 0.050 |
Why?
|
Adenosine Diphosphate Ribose | 1 | 2021 | 70 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2024 | 629 | 0.050 |
Why?
|
Exercise Test | 2 | 2020 | 2180 | 0.050 |
Why?
|
Child, Preschool | 2 | 2021 | 42500 | 0.050 |
Why?
|
Sex Factors | 1 | 2015 | 10603 | 0.050 |
Why?
|
Patient Rights | 1 | 2002 | 126 | 0.050 |
Why?
|
Heart Diseases | 1 | 2014 | 2821 | 0.050 |
Why?
|
Immunotherapy | 1 | 2017 | 4752 | 0.050 |
Why?
|
Erythropoietin | 1 | 2005 | 716 | 0.050 |
Why?
|
Hospitalization | 1 | 2021 | 10808 | 0.050 |
Why?
|
Body Composition | 3 | 2017 | 2439 | 0.050 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4353 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2016 | 3646 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2019 | 15747 | 0.040 |
Why?
|
Phthalazines | 1 | 2023 | 397 | 0.040 |
Why?
|
Purines | 1 | 2024 | 615 | 0.040 |
Why?
|
Comorbidity | 2 | 2019 | 10563 | 0.040 |
Why?
|
Education, Nursing, Continuing | 1 | 2020 | 68 | 0.040 |
Why?
|
Latin America | 1 | 2021 | 416 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 36532 | 0.040 |
Why?
|
Heart Failure | 2 | 2024 | 11840 | 0.040 |
Why?
|
Aminopyridines | 1 | 2024 | 576 | 0.040 |
Why?
|
Linear Models | 1 | 2010 | 5876 | 0.040 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 813 | 0.040 |
Why?
|
Cotinine | 1 | 2020 | 206 | 0.040 |
Why?
|
Vinblastine | 1 | 2001 | 483 | 0.040 |
Why?
|
Depressive Disorder | 1 | 2012 | 3714 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 4 | 2012 | 20659 | 0.040 |
Why?
|
Choice Behavior | 2 | 2019 | 844 | 0.040 |
Why?
|
Health Literacy | 1 | 2024 | 464 | 0.040 |
Why?
|
Contraception | 1 | 2022 | 361 | 0.040 |
Why?
|
Alcohol Drinking | 1 | 2012 | 4040 | 0.040 |
Why?
|
Motivation | 1 | 2009 | 2018 | 0.040 |
Why?
|
Arthralgia | 1 | 2022 | 459 | 0.040 |
Why?
|
Bupropion | 1 | 2020 | 303 | 0.040 |
Why?
|
Pain Threshold | 1 | 2022 | 604 | 0.040 |
Why?
|
Kidney Function Tests | 1 | 2020 | 683 | 0.040 |
Why?
|
Drug Prescriptions | 1 | 2008 | 1662 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2015 | 2229 | 0.040 |
Why?
|
Cognition Disorders | 2 | 2004 | 3967 | 0.040 |
Why?
|
Pulmonary Embolism | 1 | 2011 | 2598 | 0.040 |
Why?
|
Vulva | 1 | 2018 | 86 | 0.040 |
Why?
|
Arm | 1 | 2021 | 589 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 904 | 0.040 |
Why?
|
France | 1 | 2019 | 495 | 0.040 |
Why?
|
Poisson Distribution | 1 | 2019 | 508 | 0.040 |
Why?
|
Vacuum | 1 | 2017 | 64 | 0.040 |
Why?
|
Disability Evaluation | 2 | 1997 | 1820 | 0.040 |
Why?
|
Ultrasonography | 1 | 2011 | 5993 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 247 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6364 | 0.030 |
Why?
|
Interdisciplinary Communication | 2 | 2013 | 932 | 0.030 |
Why?
|
Austria | 1 | 2017 | 206 | 0.030 |
Why?
|
Uncertainty | 1 | 2022 | 761 | 0.030 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 350 | 0.030 |
Why?
|
Weaning | 1 | 2016 | 103 | 0.030 |
Why?
|
Reproducibility of Results | 4 | 2021 | 20124 | 0.030 |
Why?
|
Work | 1 | 1997 | 195 | 0.030 |
Why?
|
Focus Groups | 2 | 2017 | 1459 | 0.030 |
Why?
|
Filgrastim | 2 | 2006 | 131 | 0.030 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 891 | 0.030 |
Why?
|
Cell Count | 1 | 2020 | 1823 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1511 | 0.030 |
Why?
|
Ireland | 1 | 2016 | 170 | 0.030 |
Why?
|
Saliva | 1 | 2020 | 851 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1749 | 0.030 |
Why?
|
Congenital Abnormalities | 1 | 2020 | 704 | 0.030 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2016 | 169 | 0.030 |
Why?
|
Musculoskeletal Diseases | 1 | 2021 | 598 | 0.030 |
Why?
|
Creatinine | 1 | 2020 | 1915 | 0.030 |
Why?
|
Nausea | 1 | 2018 | 680 | 0.030 |
Why?
|
Watchful Waiting | 1 | 2019 | 493 | 0.030 |
Why?
|
Body Height | 1 | 2021 | 1562 | 0.030 |
Why?
|
Necrosis | 1 | 2019 | 1617 | 0.030 |
Why?
|
Vomiting | 1 | 2018 | 647 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2023 | 2570 | 0.030 |
Why?
|
Placebo Effect | 1 | 2018 | 514 | 0.030 |
Why?
|
Computers, Handheld | 1 | 2016 | 211 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2024 | 2054 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2108 | 0.030 |
Why?
|
Methylene Blue | 1 | 2014 | 157 | 0.030 |
Why?
|
GTPase-Activating Proteins | 1 | 2016 | 465 | 0.030 |
Why?
|
Insulin | 1 | 2008 | 6599 | 0.030 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 533 | 0.030 |
Why?
|
Eligibility Determination | 1 | 2016 | 423 | 0.030 |
Why?
|
Delphi Technique | 1 | 2017 | 893 | 0.030 |
Why?
|
Atrophy | 1 | 2018 | 1635 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2014 | 0.030 |
Why?
|
Demography | 1 | 1997 | 1641 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1892 | 0.030 |
Why?
|
Vagina | 1 | 2018 | 848 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2021 | 6203 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2017 | 1187 | 0.020 |
Why?
|
Anaphylaxis | 1 | 1999 | 739 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2022 | 2796 | 0.020 |
Why?
|
Preventive Medicine | 1 | 2013 | 246 | 0.020 |
Why?
|
Comprehensive Health Care | 1 | 2013 | 123 | 0.020 |
Why?
|
Pain, Postoperative | 1 | 2022 | 1772 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2020 | 2233 | 0.020 |
Why?
|
Cardiovascular Diseases | 3 | 2020 | 15652 | 0.020 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2016 | 752 | 0.020 |
Why?
|
Uterine Hemorrhage | 1 | 2013 | 235 | 0.020 |
Why?
|
Coloring Agents | 1 | 2014 | 564 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1774 | 0.020 |
Why?
|
California | 1 | 2015 | 1436 | 0.020 |
Why?
|
Schools | 1 | 2020 | 1492 | 0.020 |
Why?
|
Contraceptives, Oral | 1 | 2013 | 559 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 2140 | 0.020 |
Why?
|
Social Security | 1 | 1991 | 103 | 0.020 |
Why?
|
Quality of Health Care | 2 | 2017 | 4300 | 0.020 |
Why?
|
Nomograms | 1 | 2012 | 235 | 0.020 |
Why?
|
International Cooperation | 1 | 2017 | 1432 | 0.020 |
Why?
|
Ontario | 1 | 2011 | 402 | 0.020 |
Why?
|
Polyethylene Glycols | 2 | 2006 | 1188 | 0.020 |
Why?
|
Infertility, Male | 1 | 2013 | 395 | 0.020 |
Why?
|
Life Expectancy | 1 | 2017 | 1247 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 4642 | 0.020 |
Why?
|
Health Personnel | 2 | 2013 | 3390 | 0.020 |
Why?
|
Postpartum Period | 1 | 2016 | 1205 | 0.020 |
Why?
|
Grief | 1 | 2012 | 255 | 0.020 |
Why?
|
Pregnancy Complications | 2 | 2020 | 2975 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2013 | 614 | 0.020 |
Why?
|
Economics | 1 | 2010 | 141 | 0.020 |
Why?
|
Infant | 2 | 2022 | 36386 | 0.020 |
Why?
|
Reference Values | 1 | 2016 | 4908 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 3047 | 0.020 |
Why?
|
Ablation Techniques | 1 | 2011 | 254 | 0.020 |
Why?
|
Marital Status | 1 | 2010 | 426 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2007 | 18293 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6897 | 0.020 |
Why?
|
Estrogen Antagonists | 1 | 2008 | 150 | 0.020 |
Why?
|
Community Health Services | 1 | 2012 | 657 | 0.020 |
Why?
|
Prescriptions | 1 | 2010 | 388 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5696 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 591 | 0.020 |
Why?
|
Lymphedema | 1 | 2013 | 525 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2013 | 939 | 0.020 |
Why?
|
Hematologic Neoplasms | 1 | 2018 | 1927 | 0.020 |
Why?
|
Curriculum | 1 | 2020 | 3782 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2008 | 520 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2017 | 2778 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2006 | 6493 | 0.020 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2010 | 497 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2009 | 898 | 0.020 |
Why?
|
Animals | 4 | 2016 | 168764 | 0.020 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1471 | 0.020 |
Why?
|
Gonads | 1 | 2006 | 109 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 2017 | 1941 | 0.020 |
Why?
|
Locomotion | 1 | 1988 | 384 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2017 | 5337 | 0.020 |
Why?
|
Social Values | 1 | 2006 | 224 | 0.020 |
Why?
|
Semen Preservation | 1 | 2005 | 35 | 0.020 |
Why?
|
Goals | 1 | 2011 | 719 | 0.020 |
Why?
|
Pharmaceutical Services | 1 | 2007 | 145 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 7049 | 0.020 |
Why?
|
Internal-External Control | 1 | 2006 | 347 | 0.010 |
Why?
|
Thyroid Neoplasms | 1 | 2018 | 2371 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2022 | 9601 | 0.010 |
Why?
|
Antiemetics | 1 | 2006 | 185 | 0.010 |
Why?
|
Rheumatic Diseases | 1 | 1991 | 622 | 0.010 |
Why?
|
Blood-Brain Barrier | 1 | 2011 | 1037 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6610 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3946 | 0.010 |
Why?
|
Depressive Disorder, Major | 1 | 2021 | 4808 | 0.010 |
Why?
|
Activities of Daily Living | 2 | 1991 | 2415 | 0.010 |
Why?
|
Psychometrics | 1 | 2012 | 3062 | 0.010 |
Why?
|
Bone Diseases | 1 | 1986 | 411 | 0.010 |
Why?
|
Rheumatology | 2 | 2003 | 602 | 0.010 |
Why?
|
Prednisone | 1 | 2006 | 1565 | 0.010 |
Why?
|
Testis | 1 | 2005 | 780 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2000 | 5197 | 0.010 |
Why?
|
Quality Improvement | 1 | 2017 | 3853 | 0.010 |
Why?
|
Muscular Diseases | 1 | 1986 | 550 | 0.010 |
Why?
|
Safety Management | 1 | 2007 | 763 | 0.010 |
Why?
|
Erythrocyte Transfusion | 1 | 2005 | 568 | 0.010 |
Why?
|
Rats | 1 | 2016 | 23707 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 6309 | 0.010 |
Why?
|
Health Policy | 1 | 2012 | 2698 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 17075 | 0.010 |
Why?
|
Educational Measurement | 1 | 2006 | 1260 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2006 | 986 | 0.010 |
Why?
|
Fever | 1 | 2006 | 1603 | 0.010 |
Why?
|
Home Care Services | 1 | 1986 | 660 | 0.010 |
Why?
|
Dexamethasone | 1 | 2006 | 1963 | 0.010 |
Why?
|
Histamine H1 Antagonists | 1 | 1999 | 100 | 0.010 |
Why?
|
Algorithms | 2 | 2012 | 14071 | 0.010 |
Why?
|
Radiation Injuries | 1 | 2005 | 1181 | 0.010 |
Why?
|
Adrenergic beta-Agonists | 1 | 1999 | 345 | 0.010 |
Why?
|
Terminal Care | 1 | 2009 | 1774 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 2006 | 1808 | 0.010 |
Why?
|
Epinephrine | 1 | 1999 | 783 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2013 | 5508 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2000 | 2120 | 0.010 |
Why?
|
Medicare | 1 | 2012 | 6823 | 0.010 |
Why?
|
Signal Transduction | 1 | 2016 | 23601 | 0.010 |
Why?
|
Blood Glucose | 1 | 2008 | 6424 | 0.010 |
Why?
|
Boston | 1 | 2005 | 9338 | 0.010 |
Why?
|
Occupations | 1 | 1995 | 516 | 0.010 |
Why?
|
Education | 1 | 1995 | 533 | 0.010 |
Why?
|
Work Capacity Evaluation | 1 | 1991 | 42 | 0.010 |
Why?
|
Food Hypersensitivity | 1 | 1999 | 737 | 0.010 |
Why?
|
Mice | 1 | 2016 | 81819 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 2001 | 2067 | 0.000 |
Why?
|
Self-Help Devices | 1 | 1988 | 62 | 0.000 |
Why?
|
Sensitivity and Specificity | 1 | 1999 | 14652 | 0.000 |
Why?
|
Osteoarthritis | 1 | 1991 | 1051 | 0.000 |
Why?
|
Costs and Cost Analysis | 1 | 1986 | 1668 | 0.000 |
Why?
|
Arthritis, Rheumatoid | 1 | 1991 | 3733 | 0.000 |
Why?
|